Serum 5‐<i>S</i>‐cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients

Omodaka, Toshikazu; Minagawa, Akane; Uhara, Hisashi; Wakamatsu, Kazumasa; Koizumi, Tomonobu; Yokokawa, Yoshiharu; Koga, Hiroshi; Okuyama, Ryuhei

doi:10.1111/1346-8138.14605

Cited by 7 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Omodaka et al examined serum levels of 5SCD in 12 metastatic melanoma patients [100] and compared 5SCD and LDH levels measured before and after 3-6 weeks of treatment with nivolumab (Nivo) and their changes with the clinical responses. A decrease of 10 nmol/L or more of serum 5SCD was observed only in partial response patients (2/3 cases, 67%), while an increase of 10 nmol/L or more of serum 5SCD was seen only in progressive disease patients (4/8 cases, 50%).…”

Section: Usefulness Of 5scd In Monitoring Treatments For Melanomamentioning

confidence: 99%

See 1 more Smart Citation

Significance of 5-S-Cysteinyldopa as a Marker for Melanoma

Wakamatsu

Fukushima

Minagawa

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Melanoma is one of the most lethal and malignant cancers and its incidence is increasing worldwide, and Japan is not an exception. Although there are numerous therapeutic options for melanoma, the prognosis is still poor once it has metastasized. The main concern after removal of a primary melanoma is whether it has metastasized, and early detection of metastatic melanoma would be effective in improving the prognosis of patients. Thus, it is very important to identify reliable methods to detect metastases as early as possible. Although many prognostic biomarkers (mainly for metastases) of melanoma have been reported, there are very few effective for an early diagnosis. Serum and urinary biomarkers for melanoma diagnosis have especially received great interest because of the relative ease of sample collection and handling. Several serum and urinary biomarkers appear to have significant potential both as prognostic indicators and as targets for future therapeutic methods, but still there are no efficient serum and urinary biomarkers for early detection, accurate diagnosis and prognosis, efficient monitoring of the disease and reliable prediction of survival and recurrence. Levels of 5-S-cysteinyldopa (5SCD) in the serum or urine as biomarkers of melanoma have been found to be significantly elevated earlier and to reflect melanoma progression better than physical examinations, laboratory tests and imaging techniques, such as scintigraphy and echography. With recent developments in the treatment of melanoma, studies reporting combinations of 5SCD levels and new applications for the treatment of melanoma are gradually increasing. This review summarizes the usefulness of 5SCD, the most widely used and well-known melanoma marker in the serum and urine, compares 5SCD and other useful markers, and finally its application to other fields.

show abstract

Section: Usefulness Of 5scd In Monitoring Treatments For Melanomamentioning

confidence: 99%

“…The result of Nivo was determined as progressive disease. This Figure was modified with the consent of authors (Omodaka et al,[100]).…”

mentioning

confidence: 99%

Significance of 5-S-Cysteinyldopa as a Marker for Melanoma

Wakamatsu

Fukushima

Minagawa

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Analyzing 12 metastatic MM patients under nivolumab therapy, they showed that serum 5-S-CD levels decreased in 2 of 3 patients having a partial response and increased in 4 of 8 progressive cases. 20 Their results suggest the possible monitoring efficacy of 5-S-CD in the early phase of nivolumab therapy. On the other hand, the present study showed the utility of 5-S-CD as a predictive marker for the efficacy of long-term nivolumab therapy.…”

Section: Discussionmentioning

confidence: 96%

“…The results of the present study showed that among patients with advanced MM who underwent nivolumab therapy, baseline serum 5-S-CD levels >25.0 nmol/L were able to significantly predict poor prognosis. Recently, Omodaka et al 20 also described that serum 5-S-CD levels in the early treatment phase (3–6 weeks after initial administration of nivolumab) could possibly predict therapeutic responses in metastatic MM. Analyzing 12 metastatic MM patients under nivolumab therapy, they showed that serum 5-S-CD levels decreased in 2 of 3 patients having a partial response and increased in 4 of 8 progressive cases.…”

Section: Discussionmentioning

confidence: 99%

Serum 5-S-cysteinyl-dopa levels as a predictive marker for the efficacy of nivolumab in advanced malignant melanoma

et al. 2019

View full text Add to dashboard Cite

Purpose: With the recent developments in novel molecular targeted therapy such as immune-checkpoint blockades, serine/threonine-protein kinase B-Raf, and mitogen-activated protein kinase kinase inhibitors, the prognosis of advanced malignant melanoma has been improving. 5-S-cysteinyl-dopa (5-S-CD), a precursor of pheomelanin, has been previously revealed to be a useful biomarker for advanced-stage malignant melanoma, especially in patients with distant metastases. Here, we aimed to assess and compare the utility of serum 5-S-CD and lactate dehydrogenase levels as markers for predicting the effects of nivolumab in advanced malignant melanoma. Methods: Baseline serum 5-S-CD and lactate dehydrogenase levels in patients with unresectable stage IIIC and IV malignant melanoma treated with nivolumab (n = 21) were analyzed to determine their utility as predictive markers for survival. We also analyzed the prognostic value of these markers among patients with only stage IV malignant melanoma (n = 17). Results: Our analysis showed that patients with baseline serum 5-S-CD levels >25.0 nmol/L had significantly poor prognosis. In contrast, serum lactate dehydrogenase levels at the upper limit of the normal range did not exhibit such changes. Conclusions: Serum 5-S-CD levels have the potential to be an excellent predictive marker for the efficacy of nivolumab therapy in patients with advanced malignant melanoma.

show abstract

“…[ 35 ] Other reports showed that the lactate dehydrogenase and 5-S-CD combination may predict the response to dacarbazine treatment [ 36 ] and anti-programmed death-1 antibody therapy. [ 37 ] These findings indicate that it is very important to evaluate multiple factors in various combinations. This study was conducted in a small cohort of Japanese patients, and therefore it is necessary to explore the utility of the triple marker in a large cohort of different patient groups.…”

Section: Discussionmentioning

confidence: 99%

Combination of serum 5-S-cysteinyldopa, melanoma inhibitory activity and IL-8 improves the diagnostic accuracy of malignant melanoma compared with individual markers

et al. 2022

View full text Add to dashboard Cite

Early diagnosis of malignant melanoma is critical for effective treatment and reduced patient mortality. However, current clinical and histological variables show limited accuracy in diagnosis. Serum or urine level of 5-S-cysteinyldopa (5-S-CD) is a commonly used melanoma biomarker in Japan owing to its increased sensitivity compared with other melanoma markers. However, its use as a diagnostic marker has shown some limitations. Therefore, here we examined the combination of 5-S-CD with melanoma inhibitory activity, which showed sensitivity in detecting melanoma comparable with that of 5-S-CD, and interleukin-8, a cytokine linked with melanoma progression, in a cohort of Japanese patients with melanoma. Our results revealed that the triple combination of 5-S-CD, melanoma inhibitory activity, and interleukin-8 showed high diagnostic accuracy in detecting melanoma compared with each of the individual factors. Importantly, the triple marker showed specificity and utility in detecting early-stage melanoma. Our results suggest the utility of the triple marker as a diagnostic biomarker for melanoma patients.

show abstract

Serum 5‐S‐cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients

Cited by 7 publications

References 11 publications

Significance of 5-S-Cysteinyldopa as a Marker for Melanoma

Significance of 5-S-Cysteinyldopa as a Marker for Melanoma

Serum 5-S-cysteinyl-dopa levels as a predictive marker for the efficacy of nivolumab in advanced malignant melanoma

Combination of serum 5-S-cysteinyldopa, melanoma inhibitory activity and IL-8 improves the diagnostic accuracy of malignant melanoma compared with individual markers

Contact Info

Product

Resources

About